Biomarker & Molecular Testing in Prostate Cancer: An Overview

Prostate cancer occupies an unusual position in molecular oncology. For most men, it's a diagnosis established and managed by clinical stage, PSA kinetics, and histologic grade — molecular testing changes nothing. For a meaningful minority, though, a handful of genomic and protein findings now determine access to entire drug classes that would otherwise be unavailable. This overview orients you to the biomarkers that matter, grouped by what they're actually used for, and links each to the therapy class it gates. Every biomarker named here has a detail article of its own; this page is the map, not the territory.

Why Molecular Testing Matters Here

The clinical logic is straightforward. Localized prostate cancer is common and frequently indolent, so the field has historically leaned on grade and stage rather than genomics. But metastatic castration-resistant disease (mCRPC) tells a different story: it's here that specific alterations open the door to PARP inhibitors, checkpoint blockade, and radioligand therapy [2][3][5]. The evidence suggests that identifying these patients early — before they've exhausted conventional androgen-pathway options — improves the odds of matching biology to an effective drug class. Testing also carries implications beyond the individual: germline findings in genes such as BRCA2 inform cascade screening for relatives [2].

What Gets Tested, Grouped by Purpose

Diagnostic and lineage markers

The workhorse of surgical pathology is the diagnostic IHC triad: basal-cell markers (p63, high-molecular-weight cytokeratin), AMACR/P504S, and NKX3.1 [1]. Invasive carcinoma loses its basal-cell layer, so absence of basal staining alongside AMACR positivity supports malignancy in small or ambiguous foci. NKX3.1 does separate work — it confirms prostatic origin when a tumor turns up at a metastatic site of uncertain lineage [1][7]. This triad is diagnostic, not therapy-gating; it tells you what the tumor is, not how to treat it.

The TMPRSS2::ERG fusion, detectable by ERG immunohistochemistry as a surrogate, appears in roughly half of prostate cancers [8]. ERG positivity confirms neoplastic prostatic epithelium and defines a biologically distinct subset. It's a lineage and research marker rather than a treatment gate — worth naming precisely because its prominence in the literature can create the mistaken impression that it directs therapy. It doesn't.

Prognostic markers

PTEN loss, assessed by IHC or by FISH/NGS, marks more aggressive biology and correlates with worse outcomes [4][6]. It also flags patients for trials targeting the PI3K/AKT axis, though it isn't a standalone companion diagnostic. Read it as a risk signal that sharpens prognostic conversations and informs eligibility for pathway-directed studies.

Predictive and therapy-gating markers

Three findings genuinely change what a patient can receive.

Germline and somatic HRR alterations — most importantly BRCA2, but also BRCA1, ATM, and related homologous-recombination-repair genes — gate PARP inhibitor therapy in mCRPC [2][3][5]. The PROfound trial established that men with HRR alterations, particularly BRCA1/2, derived meaningful benefit from PARP inhibition over standard androgen-pathway therapy [5]. Some approved indications pair a PARP inhibitor with an androgen-receptor-pathway agent [3]. BRCA2 does double duty here: it's predictive of PARP sensitivity and prognostic of more aggressive disease [2][5].

Mismatch-repair deficiency and microsatellite instability (dMMR/MSI-H) are far less common in prostate cancer than in colorectal cancer, but they matter disproportionately when present [9]. This state gates tumor-agnostic checkpoint inhibitor therapy [9][10]. A durable-response signature tied to MMR deficiency has been described specifically in mCRPC, reinforcing that the small dMMR/MSI-H subset is worth hunting for [10].

PSMA expression functions as a theranostic marker, and it's worth being precise about how it's measured: in the treatment-gating context, PSMA status is determined in vivo by PSMA PET imaging, not by a pathology specimen [11]. PSMA-avid disease on PET gates PSMA-targeted radioligand therapy in mCRPC, an approach validated by the VISION trial, in which lutetium-177–PSMA-617 extended outcomes in men with PSMA-positive disease [11]. IHC for PSMA on tissue exists as a research adjunct, but the imaging-based read is what drives the therapy decision.

How Results Steer Treatment

The mapping from result to drug class is the heart of this page. Framed as eligibility — never as patient-directed advice — the linkages are:

| Result | Drug class it gates | |---|---| | HRR/BRCA alteration present [2][3][5] | PARP inhibitors (some indications combined with androgen-receptor-pathway inhibitors) | | dMMR/MSI-H [9][10] | Checkpoint inhibitors (tumor-agnostic) | | PSMA-positive on PET [11] | PSMA-targeted radioligand therapy | | PTEN loss [4][6] | Prognostic; trial eligibility (PI3K/AKT pathway) | | ERG positive / TMPRSS2::ERG [8] | Lineage-defining; not therapy-gating | | Diagnostic triad [1][7] | Diagnostic; not therapy-gating |

The first three rows are where a molecular result and a prescription actually meet. The remainder inform prognosis, confirm diagnosis, or open trial doors.

Specimen and Testing Realities

The practical texture here trips up more workflows than the biology does. Germline HRR testing uses blood; somatic testing uses tumor tissue (FFPE) or plasma-derived circulating tumor DNA (ctDNA) [2][3]. That distinction matters because germline and somatic results answer different questions — heritable risk versus tumor-specific vulnerability — and a complete picture often requires both.

Tissue is the reference standard for most assays, but archival prostate FFPE can be old, limited in quantity, or degraded, which is precisely where liquid biopsy earns its place. ctDNA sidesteps the need for a fresh biopsy of bone-predominant metastases, though its sensitivity falls when tumor shedding is low. Reflex testing — automatically running MMR IHC or ERG staining on qualifying specimens — reduces the risk that an actionable finding goes unlooked-for. And PSMA, again, stands apart: its treatment-relevant assessment is an imaging determination, not a specimen sent to a pathology bench [11].

What's Emerging

Several fronts are moving quickly, and they aren't moving at the same pace. PTEN loss remains firmly prognostic, useful for risk stratification and PI3K/AKT trial enrollment; the HRR-directed space, by contrast, sits much closer to routine actionability and continues to expand as combination indications accumulate [4][6][3].

The liquid-biopsy question is unsettled in a way that has real clinical stakes. Tissue and ctDNA don't always agree, and the concordance rate between them — especially for HRR calls that gate PARP therapy — is an active area of study rather than a solved problem. Then there's the matter of BRCA2 reversion mutations: tumors can restore homologous-recombination function under PARP-inhibitor pressure, and detecting these reversions in serial ctDNA may eventually explain resistance that tissue testing, frozen at a single timepoint, cannot. Watch this space; the interpretation of a single archived result may not hold across a treatment course.

A closing practical note rather than a summary. The timing of molecular testing shapes its value as much as the assay does. A germline and somatic panel drawn at the transition to castration-resistant disease gives clinicians the widest menu of options while the patient is still well enough to use them; the same panel run only after multiple lines of therapy may arrive too late to change the course. When to test, not just what to test, is the question that most often separates a finding that helps from one that merely documents.

References

1. WHO Classification of Tumours Editorial Board. Urinary and Male Genital Tumours, 5th ed. IARC, Lyon; 2022. ISBN 978-92-832-4512-4.
2. Primary literature on PARP inhibitors in HRR-altered mCRPC (e.g., PROfound, TRITON program).
3. PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer. PMC; 2024. PMCID: PMC10890352.
4. Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, et al. Clinical implications of PTEN loss in prostate cancer. Nature Reviews Urology; 2020. PMCID: PMC7472658.
5. de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer (PROfound trial). New England Journal of Medicine; 2020. PMID: 33264702.
6. Jamaspishvili T, Berman DM, Ross AE, et al. Clinical implications of PTEN loss in prostate cancer. Nature Reviews Urology; 2020. PMCID: PMC7472658.
7. Gurel B, Ali TZ, Montgomery EA, Begum S, Hicks J, Goggins M, et al. NKX3.1 as a marker of prostatic origin in metastatic tumors. American Journal of Surgical Pathology; 2010. PMCID: PMC3072223.
8. Tomlins SA, et al. Immunohistochemistry for ERG Expression as a Surrogate for TMPRSS2-ERG Fusion Detection in Prostatic Adenocarcinoma. American Journal of Surgical Pathology; 2012. PMCID: PMC3505676.
9. A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology / PMC; 2024. PMCID: PMC10939759.
10. Lemery S, et al. (FDA review); clinical data from KEYNOTE-158 and related basket trials. Pembrolizumab in dMMR/MSI-H tumors. PMCID: PMC10939759.
11. Sartor O, de Bono J, Chi KN, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (VISION trial). New England Journal of Medicine; 2021. PMID: 34161051. DOI: 10.1056/NEJMoa2107322.